Gilead Earnings Beat Estimates As Biotech Awaits Liver Disease Drug Ruling
The drug maker reported Q2 product sales of $6.9bn, more than analyst consensus for the quarter, and raised its full-year guidance.
The drug maker reported Q2 product sales of $6.9bn, more than analyst consensus for the quarter, and raised its full-year guidance.